Lily Li, MD, PhD, MBA, discusses factors for increasing incidence rates including low awareness, asymptomatic spread, and gaps in testing and care access, and strategies to increase early. She also provides a brief overview for some of the testing options for the infectious disease.
In the final episode of the short series, Akhila Kosaraju, MD, talks about changing the development paradigm and moving away from reengineering molecules of existing antibiotic classes and towards creating new ones.
Madeline McCrary, MD, explains her institution’s program as a novel way to get new mothers diagnosed and given their full-course of treatment when they are still in the hospital.
Study ascertains vaccination status of children hospitalized for Bordetella pertussis infections and assesses diagnostic value of testing modalities.
In the second episode of this short series, Akhila Kosaraju, MD, talks about how Phare Bio and Basilea Pharmaceuticals are partnering to develop antimicrobials taking them from AI molecules to clinical trials.
A nurse’s decades-long advocacy highlights how personal loss and gaps in public education have shaped ongoing challenges in hepatitis B vaccination and liver disease awareness.
A new study shows that strain-level surveillance of Staphylococcus aureus in NICUs can identify hidden transmission pathways and enable targeted interventions to reduce serious infections in vulnerable newborns.
Akhila Kosaraju, MD, provides insights around how AI is moving towards an accelerated pace of antimicrobial development in hopes of getting molecules into clinical trials and approved much faster than the current paradigm.
Study examines how clinicians consider rapid pneumonia panel test results in prescribing antibiotics in the ICU.
This week, read about genomic surveillance of Candida auris, commentary on vector-borne disease diagnostics, the latest measles numbers, and more.
The latest CDC numbers show a 2.57% increase of measles cases from week-to-week. This is a significant decrease in the percentage of cases from last week where there was a 6.1% increase.
Shionogi has been awarded a major US government contract to scale domestic manufacturing and expand the use of its antibiotic cefiderocol to combat antimicrobial resistance and high-priority biothreat pathogens.
A large cluster-randomized trial in Singapore found that releasing sterile male Wolbachia-infected mosquitoes greatly reduced dengue infections by suppressing local mosquito populations.
The inaugural MAD-ID and SIDP 2026 meeting aims to provide new infectious diseases education offerings, dynamic speakers, and strong networking opportunities for younger clinicians. SIDP President Erin McCreary, PharmD, BCIDP, FIDSA, offers some insights around the upcoming event.
Investigators identified behavioral determinants of being tested for pathogen exposure, in interviewing a focus group presented with a hypothetical avian influenza outbreak.
Early adoption of genomic surveillance and rigorous infection prevention protocols has enabled one health system to prevent in-hospital outbreaks of Candida auris despite rising cases nationwide. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP) provides insights on how his institution is handling testing for this problematic fungal infection.
Kyle Rodino, PhD, D(ABMM), discusses the incidence rates of Lyme disease, the emergence of mosquito-borne disease, and diagnostics including the tried-and-true tests and the emergence of metagenomic next-generation sequencing (mNGS) and AI-assisted microscopy and their roles in detecting organisms and pathogens.
Increased rapid antigen diagnostic testing for respiratory syncytial virus (RSV) in pediatric outpatients was associated with fewer antibiotic prescriptions for respiratory tract infections.
This week, read about omadacycline as an oral treatment option for Mycobacterium abscessus pulmonary disease, combining immunotherapy with antifungals for fungal infections, this year's Peggy Lillis Foundation's C diff meeting, and more.
The latest CDC numbers show a 6.1% increase of measles cases from week-to-week. This is a slight increase in the percentage of cases from last week where there was a 5.92% increase.
In the second part of our conversation with the Peggy Lillis Foundation’s CEO Christian Lillis, he discusses the agenda for their annual visit to Capitol Hill to advocate for the most significant issues affecting people with C diff to members of Congress.
Peggy Lillis Foundation’s annual event will have a number of speakers addressing these Clostridioides difficile (C diff)-related issues as they look to draw awareness to shortcomings in both areas as well as others. The organization's CEO Christian John Lillis offers some insights around the upcoming meeting.
Stakeholders offer some insights around the challenges and potential solutions including a federal investment in the field.
TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, offers some insights on the disease burden, and an overview of his company’s pipeline around developing a therapy for this STI.
In the final installment of the short series around fungal infections, Jatin Vyas, PhD, MD, discusses the challenges of developing antifungals.
The organization announced this year's event, which aims to bring together stakeholders in Washington, DC, to advance awareness, policy, and patient-centered solutions for Clostridioides difficile infection.
In the second installment of the short series around fungal infections, Jatin Vyas, PhD, MD, discusses the increase in Candida auris including its unique clades and past challenges in diagnosing this difficult-to-treat infection.
In 2018, the FDA approved omadacycline as a new oral/intravenous third generation tetracycline to treat Community Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Here is a clinical overview of omadacycline as well as recent phase 2 clinical trial results favoring oral omadacycline as an oral treatment option for Mycobacterium abscessus pulmonary disease.
Jatin Vyas, PhD, MD, discusses where the research is headed as it takes a page from the oncology world in trying to harness the immune system and combining with fungal therapeutics to treat these difficult infections.
Martin Gartland, PhD, discusses early data on the investigational therapy, VH184, including the potential for long-acting treatment and looking to address emerging drug resistance challenges.
